Agomab Reports Positive Phase 2a Results for Ontunisertib in Fibrostenosing Crohn’s Disease

FDA Expands RINVOQ® Indication for Inflammatory Bowel Disease

AstraZeneca Partners with Immunai in $85M AI-Driven IBD Deal

Phase 4 Study: Vedolizumab More Effective in Early Crohn’s Disease

CU Anschutz Study Links MAIT Cells to Gut Inflammation

SMC Approves TREMFYA® for Crohn’s Disease and Ulcerative Colitis

MRC Researchers Uncover Cell Mechanism Behind Crohn’s Fistulas

Numab and Kaken Partner on First-in-Class Multispecific Antibody for IBD

Sarah Sherlock

Head of Clinical Imaging, Early Clinical Development AstraZeneca

Thursday 2nd April 2026

Integrating Imaging-Based Biomarkers to Advance Precision in IBD Clinical Trials

1:15 pm

Maximizing the value of endoscopy by driving consistency in centralized reads
Opportunities and challenges with deploying MRI based biomarkers in global clinical trials
Emerging opportunities for AI tools to automate and accelerate central reviews